Study #2020-0672
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations
MD Anderson Study Status
Enrolling
Treatment Agent
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Description
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.